IFRX · InflaRx NV
United States · RS rating 53 · As of 2026-11-03
| Price | 1.62 USD |
|---|---|
| 1-day change | -8.2% |
| RS rating (overall / 1M / 3M / 12M) | 53 / 48 / 49 / 61 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 26 / 34 / 35 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -12.5% |
| Sales growth Q/Q | -242.4% |
| Distance from 52-week high | +40.9% |
| Market cap (USD) | $112.8M |